Transforaminal Endoscopic Lumbar Discectomy versus Coblation Nucleoplasty Combined with Collagenase Chemonucleolysis for Lumbar Disc Herniation with Grade I Degenerative Spondylolisthesis

经椎间孔内镜腰椎间盘切除术与低温等离子射频消融联合胶原酶化学溶解术治疗伴有I级退行性腰椎滑脱的腰椎间盘突出症的比较

阅读:1

Abstract

INTRODUCTION: To investigate the short-term clinical effect of transforaminal endoscopic lumbar discectomy (TELD) versus coblation nucleoplasty (CN) combined with collagenase chemonucleolysis (CCNL) in the treatment of lumbar disc herniation (LDH) with grade I degenerative spondylolisthesis. METHODS: From January 2019 to December 2020, 60 patients who had LDH with grade I degenerative spondylolisthesis were divided into two groups. Group A adopted TELD while Group B adopted CN combined with CCNL. The surgical efficacy was evaluated according to the visual analogue scale (VAS), oswestry disability index (ODI), quality of recovery-15 (QoR-15), and modified MacNab criteria. Imaging findings including lumbar lordosis (LL), segmental lordosis angle (SL), slip percentage (SP), and disc height (DH) were compared between the two groups pre-operation and at the last follow-up. RESULTS: VAS (back and leg), ODI, and QoR-15 were significantly decreased at each time point after operation in all groups. There were significant differences in VAS (back and leg), ODI, and QoR-15 between the two groups at 3 days post-operation (P < 0.05), VAS (leg), ODI, and QoR-15 at 3 months post-operative (P < 0.05), and QoR-15 at 6 months post-operative (P < 0.05). There was no significant difference in LL, SL, SP, and DH between the two groups at the last follow-up (P > 0.05). CONCLUSION: Both the two operations can relieve the symptoms of lower back and leg pain in patients, and neither of the two operations caused further progress of lumbar spondylolisthesis. Compared with CN combined with CCNL, TELD had more significant improvement in early lower back and leg pain and shorter post-operative duration of hospitalization. TRIAL REGISTRATION: The trial was registered on ClinicalTrials.gov (ChiCTR2300076809).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。